{"id":2209,"date":"2023-04-26T10:23:58","date_gmt":"2023-04-26T10:23:58","guid":{"rendered":"https:\/\/dianhuaminglu.com\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e6%99%9a%e6%9c%9f%e8%82%be%e7%bb%86%e8%83%9e%e7%99%8c%e4%b8%80%e7%ba%bf%e6%b2%bb%e7%96%97\/"},"modified":"2023-05-04T10:34:11","modified_gmt":"2023-05-04T10:34:11","slug":"%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e6%99%9a%e6%9c%9f%e8%82%be%e7%bb%86%e8%83%9e%e7%99%8c%e4%b8%80%e7%ba%bf%e6%b2%bb%e7%96%97","status":"publish","type":"post","link":"https:\/\/dianhuaminglu.com\/zh-hant\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e6%99%9a%e6%9c%9f%e8%82%be%e7%bb%86%e8%83%9e%e7%99%8c%e4%b8%80%e7%ba%bf%e6%b2%bb%e7%96%97\/","title":{"rendered":"\u541b\u5be6\u751f\u7269\u7279\u745e\u666e\u5229\u55ae\u6297\u7528\u65bc\u665a\u671f\u814e\u7d30\u80de\u764c\u4e00\u7dda\u6cbb\u7642\u7684III\u671f\u81e8\u5e8a\u7814\u7a76\u9054\u5230\u4e3b\u8981\u7814\u7a76\u7d42\u9ede\uff0c\u53ef\u986f\u8457\u5ef6\u9577\u7121\u9032\u5c55\u751f\u5b58\u671f"},"content":{"rendered":"\n
\u5317\u4eac\u6642\u95932023\u5e744\u670826\u65e5\uff0c\u541b\u5be6\u751f\u7269\uff081877.HK\uff0c688180.SH\uff09\u5ba3\u4f48\uff0c\u7531\u516c\u53f8\u81ea\u4e3b\u7814\u767c\u7684\u6297PD-1\u55ae\u6297\u85e5\u7269\u7279\u745e\u666e\u5229\u55ae\u6297\u806f\u5408\u963f\u6614\u66ff\u5c3c\u7528\u65bc\u4e2d\u9ad8\u5371\u7684\u4e0d\u53ef\u5207\u9664\u6216\u9060\u8655\u8f49\u79fb\u6027\u814e\u7d30\u80de\u764c\uff08RCC\uff09\u60a3\u8005\u4e00\u7dda\u6cbb\u7642\u7684\u591a\u4e2d\u5fc3\u3001\u96a8\u6a5f\u3001\u958b\u653e\u3001\u967d\u6027\u85e5\u5c0d\u7167\u7684III\u671f\u81e8\u5e8a\u7814\u7a76\uff08RENOTORCH\u7814\u7a76\uff09\u5df2\u5b8c\u6210\u65b9\u6848\u9810\u8a2d\u7684\u671f\u4e2d\u5206\u6790\uff0c\u7368\u7acb\u8cc7\u6599\u76e3\u67e5\u59d4\u54e1\u6703\uff08IDMC\uff09\u5224\u5b9a\u4e3b\u8981\u7814\u7a76\u7d42\u9ede\u7121\u9032\u5c55\u751f\u5b58\u671f\uff08PFS\uff0c\u57fa\u65bc\u7368\u7acb\u5f71\u50cf\u8a55\u4f30\uff09\u9054\u5230\u65b9\u6848\u9810\u8a2d\u7684\u512a\u6548\u754c\u503c\u3002\u541b\u5be6\u751f\u7269\u5c07\u65bc\u8fd1\u671f\u8207\u76e3\u7ba1\u90e8\u9580\u6e9d\u901a\u905e\u4ea4\u8a72\u65b0\u9069\u61c9\u75c7\u4e0a\u5e02\u7533\u8acb\u4e8b\u5b9c\u3002<\/p>\n\n\n\n
\u814e\u764c\u662f\u5168\u7403\u6ccc\u5c3f\u7cfb\u7d71\u7b2c\u4e09\u4f4d\u5143\u6700\u5e38\u898b\u7684\u60e1\u6027\u816b\u7624\uff0c\u800cRCC\u5360\u5168\u90e8\u814e\u764c\u75c5\u4f8b\u768480%~90%1<\/sup>\u3002\u64da\u7d71\u8a08\uff0c2022\u5e74\u4e2d\u570b\u814e\u764c\u65b0\u767c\u75c5\u4f8b\u548c\u6b7b\u4ea1\u75c5\u4f8b\u5206\u5225\u7d04\u70ba7.7\u842c\u4f8b\u548c4.6\u842c\u4f8b2<\/sup>\u3002\u7d04\u4e09\u5206\u4e4b\u4e00\u7684\u814e\u764c\u60a3\u8005\u5728\u521d\u8a3a\u6642\u5df2\u767c\u751f\u816b\u7624\u9060\u8655\u8f49\u79fb\uff0c\u800c\u5c40\u9650\u6027\u60a3\u8005\u63a5\u53d7\u814e\u5207\u9664\u8853\u5f8c\u4ecd\u670920-50%\u51fa\u73fe\u816b\u7624\u9060\u8655\u8f49\u79fb3,4<\/sup>\u3002\u57fa\u65bc\u570b\u969b\u8f49\u79fb\u6027\u814e\u7d30\u80de\u764c\u8cc7\u6599\u5eab\u806f\u76df\u7684\u98a8\u96aa\u5206\u7d1a\uff0c\u4f4e\u5371\u3001\u4e2d\u5371\u548c\u9ad8\u5371\u7684\u8f49\u79fb\u6027RCC\u60a3\u8005\u63a5\u53d7\u6297\u8840\u7ba1\u9776\u5411\u6cbb\u7642\u7684\u4e2d\u4f4d\u7e3d\u751f\u5b58\u671f\uff08OS\uff09\u5206\u5225\u70ba35.3\u300116.6\u548c5.4\u500b\u67081,5<\/sup>\u3002\u56e0\u6b64\uff0c\u76f8\u8f03\u4e8e\u4f4e\u5371\u60a3\u8005\uff0c\u4e2d\u9ad8\u5371\u665a\u671fRCC\u60a3\u8005\u5c0d\u65b0\u578b\u6cbb\u7642\u65b9\u6848\u7684\u81e8\u5e8a\u9700\u6c42\u66f4\u52a0\u8feb\u5207\u3002<\/p>\n\n\n\n \u8fd1\u5e74\u4f86\uff0c\u6d77\u5916\u5df2\u6709PD-(L)1\u6291\u5236\u5291\u806f\u5408\u6297\u8840\u7ba1\u9776\u5411\u85e5\u7269\u5728\u665a\u671fRCC\u4e00\u7dda\u6cbb\u7642\u4e0a\u53d6\u5f97\u6210\u529f\uff0c\u53d6\u4ee3\u6297\u8840\u7ba1\u9776\u5411\u85e5\u7269\u55ae\u85e5\u6cbb\u7642\u6210\u70ba\u65b0\u7684\u665a\u671fRCC\u6a19\u6e96\u4e00\u7dda\u6cbb\u7642\u65b9\u68486<\/sup>\u3002\u76f8\u8f03\u4e8e\u6297\u8840\u7ba1\u9776\u5411\u85e5\u7269\u55ae\u85e5\uff0cPD-(L)1\u55ae\u6297\u806f\u5408\u6297\u8840\u7ba1\u9776\u5411\u85e5\u7269\u6cbb\u7642\u80fd\u5920\u986f\u8457\u5ef6\u9577\u60a3\u8005\u7684PFS\uff0c\u63d0\u9ad8\u5ba2\u89c0\u7de9\u89e3\u7387\uff08ORR\uff09\uff0c\u4e26\u53ef\u89c0\u5bdf\u5230OS\u7684\u660e\u986f\u7372\u76ca\u3002\u7136\u800c\uff0c\u622a\u81f3\u76ee\u524d\uff0c\u570b\u5167\u5c1a\u7121\u4efb\u4f55PD-(L)1\u55ae\u6297\u806f\u5408\u6297\u8840\u7ba1\u9776\u5411\u85e5\u7269\u7684\u6cbb\u7642\u65b9\u6848\u7372\u6279\u7528\u65bc\u665a\u671fRCC\u4e00\u7dda\u6cbb\u7642\u3002<\/p>\n\n\n\n \u4f5c\u70ba\u570b\u5167\u9996\u500b\u665a\u671f\u814e\u764c\u514d\u75ab\u6cbb\u7642\u95dc\u9375III\u671f\u7814\u7a76\uff0cRENOTORCH\u7814\u7a76\uff08NCT04394975\uff09\u662f\u4e00\u9805\u591a\u4e2d\u5fc3\u3001\u96a8\u6a5f\u3001\u958b\u653e\u3001\u967d\u6027\u85e5\u5c0d\u7167\u7684III\u671f\u81e8\u5e8a\u7814\u7a76\uff0c\u65e8\u5728\u8a55\u4f30\u7279\u745e\u666e\u5229\u55ae\u6297\u806f\u5408\u963f\u6614\u66ff\u5c3c\u5c0d\u6bd4\u8212\u5c3c\u66ff\u5c3c\u4e00\u7dda\u6cbb\u7642\u4e2d\u9ad8\u5371\u7684\u4e0d\u53ef\u5207\u9664\u6216\u8f49\u79fb\u6027RCC\u60a3\u8005\u7684\u6709\u6548\u6027\u548c\u5b89\u5168\u6027\u3002\u6839\u64da\u672c\u7814\u7a76\u7684\u671f\u4e2d\u5206\u6790\u7d50\u679c\uff0c\u76f8\u8f03\u4e8e\u8212\u5c3c\u66ff\u5c3c\uff0c\u7279\u745e\u666e\u5229\u55ae\u6297\u806f\u5408\u963f\u6614\u66ff\u5c3c\u4e00\u7dda\u6cbb\u7642\u665a\u671fRCC\u60a3\u8005\u53ef\u986f\u8457\u964d\u4f4e\u60a3\u8005\u7684\u75be\u75c5\u9032\u5c55\u6216\u6b7b\u4ea1\u98a8\u96aa\uff0c\u540c\u6642\u6539\u5584ORR\u7b49\u6b21\u8981\u7d42\u9ede\u3002\u7279\u745e\u666e\u5229\u55ae\u6297\u5b89\u5168\u6027\u8cc7\u6599\u8207\u5df2\u77e5\u98a8\u96aa\u76f8\u7b26\uff0c\u672a\u767c\u73fe\u65b0\u7684\u5b89\u5168\u6027\u4fe1\u865f\u3002\u95dc\u65bc\u8a73\u7d30\u7684\u7814\u7a76\u8cc7\u6599\uff0c\u541b\u5be6\u751f\u7269\u5c07\u5728\u8fd1\u671f\u570b\u969b\u5b78\u8853\u5927\u6703\u4e0a\u516c\u4f48\u3002<\/p>\n\n\n\n \u541b\u5be6\u751f\u7269\u5168\u7403\u7814\u767c\u7e3d\u88c1\u9112\u5efa\u8ecd\u535a\u58eb<\/strong>\u8868\u793a\uff1a\u201c\u5728\u7814\u7a76\u8005\u3001\u60a3\u8005\u3001\u7814\u767c\u5718\u968a\u7b49\u5404\u65b9\u7684\u5171\u540c\u52aa\u529b\u4e0b\uff0cRENOTORCH\u7814\u7a76\u53d6\u5f97\u4e86\u6210\u529f\uff0c\u662f\u6211\u5011\u4f5c\u70ba\u672c\u571f\u5275\u65b0\u85e5\u4f01\u2018\u7acb\u8db3\u4e2d\u570b\u2019\uff0c\u512a\u5148\u6eff\u8db3\u570b\u4eba\u672a\u76e1\u9700\u6c42\u7684\u91cd\u8981\u5be6\u8e10\uff0c\u6b64\u6b21\u9054\u6210\u967d\u6027\u7d50\u679c\u5c07\u6709\u671b\u586b\u88dc\u570b\u5167\u814e\u764cPD-(L)1\u514d\u75ab\u6cbb\u7642\u9818\u57df\u7684\u7a7a\u767d\u3002\u6211\u5011\u5c07\u7a4d\u6975\u63a8\u52d5\u9019\u9805\u6210\u679c\u7684\u5546\u696d\u5316\u843d\u5730\uff0c\u4ee5\u671f\u70ba\u570b\u5167\u60a3\u8005\u63d0\u4f9b\u65b0\u578b\u3001\u6709\u6548\u7684\u514d\u75ab\u806f\u5408\u6cbb\u7642\u65b0\u9078\u64c7\uff01\u201c<\/p>\n\n\n\n <\/p>\n\n\n\n <\/p>\n\n\n\n <\/p>\n\n\n\n\u3010\u53c3\u8003\u6587\u737b\u3011<\/h5>\n\n\n\n
1.\u00a0\u00a0\u00a0\u00a0 \u4e2d\u83ef\u4eba\u6c11\u5171\u548c\u570b\u570b\u5bb6\u885b\u751f\u5065\u5eb7\u59d4\u54e1\u6703. \u300a\u814e\u7d30\u80de\u764c\u8a3a\u7642\u6307\u5357\uff082022\u5e74\u7248\uff09\u300b. 2022.<\/h5>\n\n\n\n
2. Xia C, Dong X, Li H, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants. Chin Med J (Engl) 2022;135:584-90.<\/h5>\n\n\n\n
3. Padala SA, Barsouk A, Thandra KC, et al. Epidemiology of Renal Cell Carcinoma. World J Oncol 2020;11:79-87.<\/h5>\n\n\n\n
4. Janzen NK, Kim HL, Figlin RA, Belldegrun AS. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am 2003;30:843-52.<\/h5>\n\n\n\n
5. Heng DY, Xie W, Regan MM, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 2009;27:5794-9.<\/h5>\n\n\n\n
6. Xu W, Atkins MB, McDermott DF. Checkpoint inhibitor immunotherapy in kidney cancer. Nat Rev Urol 2020;17:137-50.<\/h5>\n\n\n\n
1. \u672c\u6750\u6599\u65e8\u5728\u50b3\u905e\u524d\u6cbf\u8cc7\u8a0a\uff0c\u7121\u610f\u5411\u60a8\u505a\u4efb\u4f55\u7522\u54c1\u7684\u63a8\u5ee3\uff0c\u4e0d\u4f5c\u70ba\u81e8\u5e8a\u7528\u85e5\u6307\u5c0e\u3002<\/em><\/h6>\n\n\n\n
2. \u82e5\u60a8\u60f3\u77ad\u89e3\u5177\u9ad4\u75be\u75c5\u8a3a\u7642\u8cc7\u8a0a\uff0c\u8acb\u9075\u5f9e\u91ab\u7642\u885b\u751f\u5c08\u696d\u4eba\u58eb\u7684\u610f\u898b\u8207\u6307\u5c0e\u3002<\/em><\/h6>\n\n\n\n